Grigory A Tsaur

List of Publications by Year
in descending order

58	1,607	840119	344852
papers	citations	11 h-index	36 g-index

59	59	59	2925
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangements. British Journal of Haematology, 2023, 201, 510-519.	1.2	8
2	Lineage switch to acute myeloid leukemia during induction chemotherapy for early T-cell precursor acute lymphoblastic leukemia with the translocation t(6;11)(q27;q23)/KMT2A-AFDN: A case report. Leukemia Research, 2022, 112, 106758.	0.4	5
3	Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy. International Journal of Molecular Sciences, 2022, 23, 4019.	1.8	18
4	A simple algorithm with one flow cytometric MRD measurement identifies more than 40% of children with ALL who can be cured with low-intensity therapy. The ALL-MB 2008 trial results. Leukemia, 2022, 36, 1382-1385.	3.3	6
5	Suppressed miR-128-3p combined with TERT overexpression predicts dismal outcomes for neuroblastoma. Cancer Biomarkers, 2022, , 1-11.	0.8	1
6	Low-intensity therapy cures over 40 % of children with rapid Flow-MRD responding ALL: the ALL-MB 2008 trial results. Pediatric Hematology/Oncology and Immunopathology, 2022, 21, 95-104.	0.1	2
7	Prognostic significance of various 11q23/KMT2A rearrangements in infants with acute lymphoblastic leukemia. Pediatric Hematology/Oncology and Immunopathology, 2021, 20, 27-39.	0.1	2
8	Blinatumomab following haematopoietic stem cell transplantation â€“ a novel approach for the treatment of acute lymphoblastic leukaemia in infants. British Journal of Haematology, 2021, 194, 174-178.	1.2	8
9	BTK, NUTM2A, and PRPF19 Are Novel KMT2A Partner Genes in Childhood Acute Leukemia. Biomedicines, 2021, 9, 924.	1.4	5
10	Prognostic value of minimal residual disease measured by fusionâ€gene transcript in infants with KMT2Aâ€rearranged acute lymphoblastic leukaemia treated according to the MLLâ€Baby protocol. British Journal of Haematology, 2021, 193, 1151-1156.	1.2	8
11	Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols. Leukemia, 2020, 34, 3042-3046.	3.3	13
12	The role of thrombophilia genes in the clinical implementation of arterial and venous thrombosis in newborns. BIO Web of Conferences, 2020, 22, 02021.	0.1	1
13	Association of Gene Variants of Plasmic (FGB -455 G>A (rs1800790), F2 20210 G>A) Tj ETQq1 1 0.784314 rgBT /Overlock Thrombocytic (ITGA2 807 C>T (rs1126643), ITGB3 1565 T>C (rs5918)), Fibrinolytic (PAI-1) Tj ETQq1 1 0.784314 rgBT /Overlock Case-Controlled Study. PediatriÄeskaÄ¢ FarmakologiÄ¢, 2020, 17, 437-444.		
14	Clinical significance of cytogenetic changes in childhood T-cell acute lymphoblastic leukemia: results of the multicenter group Moscowâ€“Berlin (MB). Leukemia and Lymphoma, 2019, 60, 426-432.	0.6	4
15	Heterogeneity of childhood acute leukemia with mature B-cell immunophenotype. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2803-2811.	1.2	7
16	Exome, transcriptome and miRNA analysis donâ€™t reveal any molecular markers of TKI efficacy in primary CML patients. BMC Medical Genomics, 2019, 12, 37.	0.7	4
17	Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLLâ€“USP2 fusions. Leukemia, 2019, 33, 2306-2340.	3.3	41
18	IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia. Translational Oncology, 2019, 12, 726-732.	1.7	7

#	Article	IF	Citations
19	Absolute count of leukemic blasts in cerebrospinal fluid as detected by flow cytometry is a relevant prognostic factor in children with acute lymphoblastic leukemia. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1331-1339.	1.2	24
20	Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL. Blood Advances, 2019, 3, 148-157.	2.5	48
21	Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma. Journal of Cancer Research and Clinical Oncology, 2019, 145, 535-542.	1.2	15
22	Acute myeloid leukemia with t(10;11)(p11â€12;q23.3): Results of Russian Pediatric AML registration study. International Journal of Laboratory Hematology, 2019, 41, 287-292.	0.7	6
23	BCR-ABL1-like pediatric acute lymphoblastic leukemia. Pediatric Hematology/Oncology and Immunopathology, 2019, 18, 112-126.	0.1	2
24	Immunophenotypic characterization of acute megakaryoblastic leukaemia in children. Pediatric Hematology/Oncology and Immunopathology, 2019, 18, 35-40.	0.1	2
25	Prognostic Value of Minimal Residual Disease Measured By Flow Cytometry in Two Cohorts of Infants with Acute Lymphoblastic Leukemia Treated with MLL-Baby and Interfant Protocols in Large Multicenter Networks. Blood, 2019, 134, 2747-2747.	0.6	0
26	The MLL recombinome of acute leukemias in 2017. Leukemia, 2018, 32, 273-284.	3.3	527
27	Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR. Pediatric Blood and Cancer, 2018, 65, e27354.	0.8	12
28	MLL-USP2: An Underestimated New Entity of MLL-Rearranged Leukemia Identified By NGS Analysis. Blood, 2018, 132, 3920-3920.	0.6	2
29	RUSSIAN-BELARUSIAN MULTICENTER GROUP STANDARD GUIDELINES FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA FLOW CYTOMETRIC DIAGNOSTICS. Oncogematologiya, 2018, 13, 73-82.	0.1	25
30	Rare cases of laboratory tests discrepancies in diagnostics of pediatric Burkitt lymphoma/leukemia. Oncogematologiya, 2018, 13, 76-82.	0.1	0
31	Application of Real-Time PCR for the Detection of BCR-ABL1-like Group in Pediatric Acute Lymphoblastic Leukemia Patients. Blood, 2018, 132, 1376-1376.	0.6	2
32	Integrative analysis of bone marrow disease in neuroblastoma patients by DNA, RNA and protein markers. European Journal of Cancer, 2017, 72, S143.	1.3	0
33	Lack of micro-RNA 128A expression as a novel prognostic marker in neuroblastoma patients and combination with TERT hyperexpression to define patient outcomes.. Journal of Clinical Oncology, 2017, 35, e22014-e22014.	0.8	0
34	Biological microchip for establishing the structure of fusion transcripts involving MLL in children with acute leukemia. Molecular Biology, 2016, 50, 852-859.	0.4	5
35	Relapse Prediction By Flow Cytometric Minimal Residual Disease Assessment in Infants with Acute Lymphoblastic Leukemia. Blood, 2016, 128, 1731-1731.	0.6	0
36	ÐŸÐµÑ€ÐµÑ‚Ð¾Ð¿Ð¸ Ñ…Ñ€Ð¾Ð¼Ð¾ÑÐ¾Ð¼Ð½Ð¾Ð¹ Ð¿ÐµÑ€ÐµÑ‚Ð°ÑÐ¾Ð²ÐºÐ¸ 11q23 Ð¿Ñ€Ð¸ Ð¾ÑÑ‚Ñ€Ð¾Ð¼ Ð»Ð¸Ð¼Ñ„Ð¾Ð±Ð»Ð°ÑÑ‚Ð½Ð¾Ð¼		

#	Article	IF	Citations
37	1400 Prognostic significant copy number variations (CNVs) defined by MLPA in primary and relapsed neuroblastomas (NB). European Journal of Cancer, 2015, 51, S197-S198.	1.3	0
38	A new variant of KMT2A(MLL)-FLNA fusion transcript in acute myeloid leukemia with ins(X;11)(q28;q23q23). Cancer Genetics, 2015, 208, 148-151.	0.2	9
39	Abstract 1626: Evaluation of the expression of neuroblastoma-associated genes for bone marrow (BM) involvement and minimal residual disease (MRD) detection. , 2015, , .		0
40	Are non-cystic fibrosis bronchiectasis a result of primary antibody deficiency?. , 2015, , .		0
41	Detection of Translocation t(7;12)(q36;p13) in Infants with Acute Myeloid Leukemia By Novel 3-Color Fluorescent in Situ Hybridization Approach. Blood, 2015, 126, 3827-3827.	0.6	0
42	Prognostic impact of copy number variations in neuroblastoma patients.. Journal of Clinical Oncology, 2014, 32, e21009-e21009.	0.8	0
43	Abstract 1900: Prognostic significance of genetic aberrations in neuroblastoma. , 2014, , .		0
44	Concordance and Prognostic Significance of Minimal Residual Disease Detection in Peripheral Blood and Bone Marrow Samples of Infants with MLL-rearranged Acute Lymphoblastic Leukemia Treated By MLL-Baby Protocol. Blood, 2014, 124, 2404-2404.	0.6	0
45	The MLL recombinome of acute leukemias in 2013. Leukemia, 2013, 27, 2165-2176.	3.3	393
46	A Novel Three-Colour Fluorescence in Situ Hybridization Approach for the Detection of t(7;12)(q36;p13) in Acute Myeloid Leukaemia Reveals New Cryptic Three Way Translocation t(7;12;16). Cancers, 2013, 5, 281-295.	1.7	11
47	MLL genomic DNA Breakpoints In Infant Acute Leukemia. Blood, 2013, 122, 1350-1350.	0.6	3
48	Identification Of Low Risk Group In Infants With Acute Lymphoblastic Leukemia By Flow Cytometric Minimal Residual Disease Measurement At Day 15 Of Interfant-99 and Interfant-06 Protocols Treatment. Blood, 2013, 122, 1333-1333.	0.6	0
49	Molecular Genetic Characterization of 3'-Deletion of MLL Gene in Infant Acute Leukemia.. Blood, 2012, 120, 2498-2498.	0.6	0
50	4122 POSTER Application of NKX2, STEAP1 and CCND1 Genes Expression for Bone Marrow Involvement Detection in Patients With Ewing Family Tumours. European Journal of Cancer, 2011, 47, S290.	1.3	0
51	Does ATRA Confirm to Play a Role in the Better Relapse Free Survival of Infants with Acute Lymphoblastic Leukemia?. Blood, 2011, 118, 1515-1515.	0.6	2
52	Flow Cytometric Leukemic Blasts Detection in Cerebrospinal Fuid of Children with Acute Leukemias. Blood, 2011, 118, 1449-1449.	0.6	0
53	Qualitative and Quantitative Concordance of Minimal Residual Disease Data Assessed by Multicolor Flow Cytometry and PCR of Fusion Gene Transcripts In Childhood B-Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2010, 116, 1720-1720.	0.6	0
54	Minimal Residual Disease Monitoring by Quantification of Fusion Gene Transcripts In Infant with MLL-rearranged Acute Lymphoblastic Leukemia Treated by MLL-Baby Protocol. Blood, 2010, 116, 2731-2731.	0.6	0

#	Article	IF	Citations
55	New insights to the MLL recombinome of acute leukemias. Leukemia, 2009, 23, 1490-1499.	3.3	363
56	Contribution of All-Trans Retinoic Acid to Improved Early Relapse-Free Outcome in Infant Acute Lymphoblastic Leukemia Comparing to the Chemotherapy Alone.. Blood, 2007, 110, 2828-2828.	0.6	12
57	Molecular Remission in MLL/AF4-Positive Infant Leukemia Treated with the All Trans-Retinoic Acid Based MLL-Baby Protocol.. Blood, 2007, 110, 4254-4254.	0.6	2
58	Unusual Immunophenotypes in the Bone Marrow of Infants with Acute Leukemia: Minimal Residual Disease or ATRA-Mediated Regeneration?.. Blood, 2007, 110, 4260-4260.	0.6	0